SB-284851-BT
Product Specifications
UNSPSC Description
SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1)(IC50=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET)[1][2].
Target Antigen
Epigenetic Reader Domain; p38 MAPK
Type
Reference compound
Related Pathways
Epigenetics;MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sb-284851-bt.html
Solubility
10 mM in DMSO
Smiles
FC1=CC=C(C2=C(C3=NC(OC4=CC(C)=CC(C)=C4)=NC=C3)N(C5CCNCC5)C=N2)C=C1
Molecular Weight
443.52
References & Citations
[1]Divakaran A, et al. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem. 2018 Oct 25;61(20):9316-9334. |[2]Jin W, et al. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discov Today. 2022 Jan;27(1):246-256.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-136794/SB-284851-BT-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-136794/
Clinical Information
No Development Reported
CAS Number
219769-23-0
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
